Stewart Kay, formerly of GlaxoSmithKline Plc, has joined Crescendo Biologics Ltd as chief business officer as the company advances its lead product towards the clinic. Mr Kay was most recently senior director for transactions at GSK having led negotiations for a wide variety of deals across the oncology, immuno-inflammation, respiratory and rare disease areas. His experience covers early and late-stage clinical and preclinical asset transactions. Before joining GSK, he held senior roles in business development and marketing at Asterand Plc, Evotec SE and Amersham Biosciences (now GE Healthcare).
Mr Kay holds a Bachelor of Science degree in biochemistry and an MBA from Warwick University Business School.
Crescendo Biologics announced the appointment on 5 September 2019.
Copyright 2019 Evernow Publishing Ltd.